Navigation Links
D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
Date:6/8/2009

REHOVOT, Israel, June 8 /PRNewswire/ -- D-Pharm announced today that its Investigational New Drug (IND) application for a pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients has been approved by the US Food and Drug Administration (FDA). D-Pharm plans to initiate the trial in the coming months, in over 100 clinical sites in North America, Europe, South Africa and Israel.

The forthcoming Phase III trial is a randomized, double blind, placebo-controlled study (study acronym MACSI: Membrane Activated Chelator Stroke Intervention). It is designed to compare the effect on ischemic stroke outcome between a placebo group and a group of patients treated with 1 mg/kg/day of DP-b99 for 4 consecutive days. D-Pharm plans to enroll 770 moderate to severely affected ischemic stroke patients worldwide, with first patients expected to be recruited in Israel and South Africa.

Dr. Gilad Rosenberg, D-Pharm's VP Clinical Development commented, "The FDA's IND procedure involved review of the entire DP-b99 data set. Following 30 days for review of our IND application, the FDA has no further questions relating to DP-b99's CMC, preclinical and clinical data package. I'm very pleased that the Agency is satisfied with our data and we can move forward with this important study without delay."

Prior to the IND submission D-Pharm successfully completed the program outlined at the pre-IND meeting held with the FDA in January 2008. The program included additional toxicity studies, a drug interaction study with rtPA, and an interaction study with warfarin in healthy volunteers, as well as scale-up and optimization of the DP-b99 manufacturing process.

About DP-b99

DP-b99 is a unique neuroprotective drug that addresses an array of brain damaging processes occurring in stroke patients and emerged from D-Pharm's proprietary Membrane Activated Chelator (MAC) platform technolog
'/>"/>

SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. D-Pharm Secures Funding From Israels Chief Scientists Office
2. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
3. Yongye Biotechnology International Receives License to Manufacture Products
4. EarlySenses EverOn(TM) System Receives FDA Clearance and CE Mark Certification
5. Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners
6. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
7. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
8. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
9. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
10. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
11. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... -- A new therapy developed by researchers at ... of Medicine and Columbia University Medical Center (CUMC) ... cardiovascular disease treatment. , The researchers demonstrated ... therapy could selectively inhibit blood vessel re-narrowing and ... using a balloon catheter to open narrowed or ...
(Date:8/18/2014)... with unprecedented efficiency and data storage may ... built-in electric polarizations to read and write ... popular data-driven technology. But ferroelectrics must first ... a curious habit of "forgetting" stored data. ... Department of Energy,s Brookhaven National Laboratory have ...
(Date:8/18/2014)... Fla. , Aug. 18, 2014 TNI ... biotechnology company pioneering the manufacturing and marketing of innovative ... that the Company is providing a second notice of ... In making the announcement, Noreen Griffin , ... you in advance for your participation in the Annual ...
(Date:8/16/2014)... (PRWEB) August 16, 2014 Firms ... industry provide guidance and advisory services to businesses, ... technical issues. Industry services are highly diverse as ... industry services range from geological and geophysical consulting ... “Consequently, over the past five years, the recovery ...
Breaking Biology Technology:Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3
... CHICAGO and HOBOKEN, N.J. , Aug. 2 ... Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & ... program supports clinical or pre-clinical research focused on human protein therapies in hematology, ... , , ...
... 2 Tengion Inc. (Nasdaq: TNGN ) ... the position of Chief Financial Officer.  Mr. Davis comes to Tengion after ... to develop improved protein therapeutics. At its peak, Neose employed 200 individuals, ... , , ...
... LAUSANNE , Switzerland , August 2, 2010 ... its Global Films,business to Bilcare AG, one of the world,s leading providers ... . The agreement brings together complimentary capabilities and,synergy,s of two leading global ... ...
Cached Biology Technology:Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Tengion Appoints A. Brian Davis Chief Financial Officer 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 3
(Date:8/19/2014)... made to decrease China,s increasing caesarean section rate, suggests ... BJOG: An International Journal of Obstetrics and Gynaecology (BJOG) ... delivery rates in the world. Of 16 million babies ... the exact rate is not known, the current Chinese ... caesarean rates ranging from 36% to 58%. However, before ...
(Date:8/19/2014)... HOUSTON, Aug. 19, 2014 To improve students, ... poor grades, the University of Houston (UH) implemented ... for students at risk for failure. , ... Coordinating Board (THECB), the Department of Biology and ... first-year students taking "General Biology" for non-majors and ...
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... the Younger Dryas interval, which saw a rapid return ... it has been assumed that cooling temperatures and their ... groups. David Meltzer from the Southern Methodist University ... of Arizona in Tucson, USA, suggest otherwise in their ...
... MADISON, WI, April 12, 2010-What do obesity trends ... in Kenya, or alternative soil conservation strategies in Peru ... food and agriculture issues, and represent the world,s interdependence ... to build experiences of a broad and diverse world, ...
... Researchers at the Walter and Eliza Hall Institute have ... the female hormones oestrogen and progesterone, a finding that ... and treatments for breast cancer. The discovery, by ... Bioinformatics divisions, also explains decades of evidence linking breast ...
Cached Biology News:Bringing the world of agriculture to the classroom 2Hormone sensitivity of breast stem cells presents drug target 2
... Immunogen: synthetic peptide corresponding to the third ... dopamine receptor, conjugated to KLH. The immunizing ... and mouse gene. Physical form: Solution ... 0.01% sodium azide. Titertest method: IHC ...
Canine Chondrocytes (CnC) (500,000 cells)...
... Fluorescein 6-Fam, Hex, Tet Cy3, ... Fluorescein Tamra Black Hole Quenchers Molecular ... Tet Tamra, Joe 3 Dabcyl ... New York Double labelled probes are purified ...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Biology Products: